Congress quietly expands no-bid contracts for drug makers in biodefense bill

What it does

This bill expands the Biomedical Advanced Research and Development Authority (BARDA) within the Department of Health and Human Services to award follow-on production contracts without competitive bidding to companies that win initial prototype development contracts, procure supplies for experimental purposes using non-competitive procedures, and acquire innovative commercial products through a streamlined process. Companies that develop prototypes for BARDA can now be awarded production contracts directly, bypassing normal competitive procurement rules, provided the initial prototype selection used competition.

Why we flagged it

The bill's core function is to expand BARDA's contracting flexibility, but the operative mechanism—allowing non-competitive follow-on production contracts—represents a significant departure from standard federal procurement rules. The title (FLASH Act) obscures this procurement deregulation behind emergency-response framing.

What the text implies

• Follow-on production contracts can be awarded without competitive bidding if the initial prototype selection was competitive, creating a two-stage process where only the first stage faces price competition. Subsequent production orders—potentially worth far more than prototype development—escape competitive pressure.
• The $100M threshold for written efficacy determination is high; contracts just under this amount face no such review, and even those above it require only a written determination, not external approval or competitive justification.
• Non-competitive procurement for 'experimental or test purposes' is undefined in scope—the Secretary determines what qualifies, with no requirement for advance notice or competitive procedures, creating discretionary spending authority.
• The 45-day post-award notification requirement for contracts over $100M is a disclosure mechanism, not a prevention mechanism; Congress cannot block the award, only be informed after the fact.
• Fixed-price contract requirement may incentivize cost-cutting and quality shortcuts, particularly if the initial prototype developer has already captured the production contract and faces no competitive threat.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill may accelerate development of critical medical countermeasures and emergency supplies during public health crises, a genuine public benefit. However, it creates a significant pathway for non-competitive procurement of production contracts worth potentially billions of dollars, reducing transparency and competitive pressure on pricing, which may increase costs to taxpayers and reduce accountability in how public health dollars are spent.

Who stands to gain

• pharmaceutical manufacturers (prototype developers eligible for follow-on production contracts)
• medical device companies
• contract research organizations
• commercial suppliers of medical countermeasures

Named in the bill

BARDA (Biomedical Advanced Research and Development Authority), Department of Health and Human Services (HHS), Section 319L of the Public Health Service Act, House Committee on Energy and Commerce, Senate Committee on Health, Education, Labor, and Pensions, Bristol Myers Squibb (BMY), Gilead Sciences (GH), Pfizer (PFE), DaVita (DVA), Johnson & Johnson (JNJ)

Where it stands

• Jan 28, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jan 28, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.